When was US World Meds founded?

US World Meds was founded in 2001 and raised its 1st funding round 4 years after it was founded.

Where is US World Meds located?

US World Meds is headquartered in Louisville, United States. It is registered at Louisville, Kentucky.

How many employees does US World Meds have?

As of Dec 31, 2019, the latest employee count at US World Meds is 216.

Is US World Meds a funded company?

US World Meds is a funded company, having raised a total of $149M across 8 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 01, 2005.

When was the latest funding round of US World Meds?

US World Meds' latest funding was a $***** Grant (prize money) round on Jul 17, 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.1B in funding in 2026 to date.

Where does US World Meds rank among its competitors?

US World Meds ranks 11th amongst 457 active competitors, of which 161 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Mission Therapeutics, which secured $13.3M in Oct, 2025.

Who are the top competitors of US World Meds?

US World Meds' top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Mission Therapeutics secured the most recent funding round in October, 2025.

US World Meds - 2026 Company Profile, Team, Funding & Competitors

US World Meds is a series B company based in Louisville (United States), founded in 2001. It operates as a Developer of therapeutics for the treatment of multiple diseases. US World Meds has raised $149M in funding. The company has 457 active competitors, including 161 funded and 82 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.

Company Details

Developer of therapeutics for the treatment of multiple diseases. The company's drugs include APOKYN (apomorphine hydrochloride injection for Parkinson's disease), CORGARD (nadolol tablets for hypertension, angina pectoris), MYOBLOC (rimabotulinumtoxinB Injection for cervical dystonia), REVONTO (dantrolene sodium injection for anesthetic-induced malignant hyperthermia syndrome) and XADAGO (safinamide tablets for Parkinson's Disease).

Website: usworldmeds.com
Social
Email ID: *****@usworldmeds.com
Phone Number: +1 **********
Registered Address: Louisville, Kentucky

Key Metrics

Founded Year

2001

Location

Louisville, United States

Stage

Series B

Total Funding

$149M in 8 rounds

Latest Funding Round

Grant (prize money), Jul 17, 2025, $*****

Investors

Athyrium Capital Management & 7 more

Ranked

11^th among 457 active competitors

Employee Count

216 as on Dec 31, 2019

Investment & Acquisitions

Solstice Neurosciences

Similar Companies

Denali Therapeutics & 567 more

View US World Meds' full profile

US World Meds is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
US WORLDMEDS LLC CIN: 611387427 , United States, Active	Dec 26, 999	-	216 (As on Dec 31, 2019)	-

US World Meds has raised a total funding of $149M over 8 rounds. Its first funding round was on Jul 01, 2005. Its latest funding round was a Grant (prize money) round on Jul 17, 2025 for $*****. 1 investor participated in its latest round. US World Meds has 8 institutional investors.

Here is the list of recent funding rounds of US World Meds:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 17, 2025	4747608	Grant (prize money)	2105680	5310094	1041870	7970722
Apr 02, 2025	5900620	Grant (prize money)	3291010	2843575	7983267	HHS
Mar 18, 2025	9570635	Grant (prize money)	2521634	2686494	2092889	HHS

Access funding benchmarks and valuations. Sign up today!

View details of US World Meds's funding rounds and investors

US World Meds' employee count trend

US World Meds has 216 employees as of Dec 19. The total employee count is 1.0% lower than what it was in Dec 18. Here is US World Meds's employee count trend over the years:

Uncover US World Meds' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of US World Meds include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of US World Meds, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 17 others	67/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
8th	Athira Pharma 2011, Seattle (United States), Public	Developer of drugs for neurodegenerative diseases	$121M	Dolby Family Ventures, Alzheimer's Drug Discovery ... & 22 others	65/100
9th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$115M	RA Capital Management, SV Health Investors ... & 13 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
11th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100